This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hizuka, N. Articles by Demura, H. Search for Related Content PubMed PubMed Citation Articles by Hizuka, N. Articles by Demura, H.

Serum High Molecular Weight Form of Insulin-Like Growth Factor II from Patients with Non-Islet Cell Tumor Hypoglycemia Is O-Glycosylated¹

Department of Medicine II, Tokyo Women’s Medical University, Tokyo, 162-8666, Japan

Address all correspondence and requests for reprints to: Naomi Hizuka, Department of Medicine II, Tokyo Women’s Medical University, 8–1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan. E-mail: naomi-hi{at}hi-ho.ne.jp

Non-islet cell tumor hypoglycemia (NICTH) is one of major causes of fasting hypoglycemia. In some patients with NICTH, insulin-like growth factor II (IGF-II) produced by and secreted from the tumors is thought to be a hypoglycemic agent. In patients with NICTH, the major form of IGF-II is high molecular weight form of IGF-II, designated as big IGF-II. The generation of big IGF-II in the NICTH syndrome is unclear. It has been reported that in the patients with NICTH big IGF-II lacks normal E-domain O-linked glycosylation, suggesting that the patient’s big IGF-II might be generated by abnormal processing of pro-IGF-II. However, we have found that the apparent size of big IGF-II varies in sera from the patients with NICTH, and that there is a possibility that slower migration pattern of IGF-II might be because of a different size of sugar moiety attached to pro-IGF-II. In the present study using the sera from 10 patients with NICTH, we investigated the effect of O-glycosidase digestion on migration of IGF-II and analyzed the results by Western immunoblot. By Western immunoblot analysis the big IGF-II was reduced in size to 9.5 kDa in the enzyme-treated sera of the 10 patients with NICTH. The migration pattern is similar to that observed in sera of normal subjects after O-glycosidase digestion. These data indicate that big IGF-II from patients with NICTH is O-glycosylated, and the sizes of the sugar moiety are larger than those from normal subjects suggesting abnormal glycosylation in NICTH.

This article has been cited by other articles:

				K. Kameyama, N. Okumura, Y. Kokado, K. Miyoshi, T. Matsuoka, and T. Nakagawa Solitary Fibrous Tumor Associated With Non-Islet Cell Tumor Hypoglycemia Ann. Thorac. Surg., July 1, 2007; 84(1): 292 - 294. [Abstract] [Full Text] [PDF]

				K. Kato, C. Jeanneau, M. A. Tarp, A. Benet-Pages, B. Lorenz-Depiereux, E. P. Bennett, U. Mandel, T. M. Strom, and H. Clausen Polypeptide GalNAc-transferase T3 and Familial Tumoral Calcinosis: SECRETION OF FIBROBLAST GROWTH FACTOR 23 REQUIRES O-GLYCOSYLATION J. Biol. Chem., July 7, 2006; 281(27): 18370 - 18377. [Abstract] [Full Text] [PDF]

				S. Khosla, F. J. Ballard, and C. A. Conover Use of Site-Specific Antibodies to Characterize the Circulating Form of Big Insulin-Like Growth Factor II in Patients with Hepatitis C-Associated Osteosclerosis J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3867 - 3870. [Abstract] [Full Text] [PDF]